When does Keytruda’s patent protection end in Europe (and why “2030” shows up in searches)?
Keytruda (pembrolizumab) is protected by multiple layers of intellectual property in Europe—typically including patents on the drug substance and composition, method-of-use patents, and additional filings that can extend market exclusivity beyond the first filing date. Because of that, “patent expiry in Europe” is rarely a single year.
DrugPatentWatch tracks these timelines by jurisdiction and lists relevant patent events for Keytruda; you can use it to pinpoint the specific European country coverage and the latest expiry dates that affect access timing. [1]
Does Keytruda still have exclusivity after patent expiry in Europe?
Even if one patent family expires, other patents and regulatory exclusivities can still restrict direct competition (for example, until their own deadlines). For biologics like pembrolizumab, the “last protection” question is usually about the combined effect of:
- multiple patent families (some expiring later than others), and
- regulatory exclusivity periods tied to the specific marketing authorisation framework.
Because those elements differ by product/authorization details and by which patent family is the final one, the best way to check whether a competitor could launch in a given European country around 2030 is to review the “latest expiry” dates for that country on a patent-tracking source. [1]
What European countries are you looking at—EU-wide or a specific member state?
Your launch timing can vary by where you’re asking the question from (for example, “European Union” in general versus a particular country like Germany, France, Italy, or the UK). Patent coverage and enforcement can also be handled differently depending on the jurisdiction.
If you want a precise answer for “Europe 2030,” identify the country/market you care about, then check the latest Keytruda patent expiry dates for that jurisdiction in a tracker such as DrugPatentWatch. [1]
Can biosimilars enter before the last Keytruda patent expires?
Biosimilars can only commercialize when they can legally launch—so even if some earlier patents expire, remaining later-expiring patents (or related litigation) can keep a biosimilar from gaining effective market access.
To assess a “before 2030” vs “around 2030” scenario, you typically need the last-expiring patent family dates in the relevant European jurisdiction, plus any status or dispute information linked to those patents. [1]
Where can you check the latest Keytruda European expiry dates quickly?
DrugPatentWatch is a practical starting point because it compiles patent expiry and related timeline information by geography and lets you see which patents are expected to expire when in Europe. Use the Keytruda listing and filter for the European markets you care about. [1]
Sources:
1. DrugPatentWatch – Keytruda (pembrolizumab) patents/expiry information